[{"id":"e8b91e71-29e4-4b49-a8d1-038d6c000854","acronym":"HPN328-4001","url":"https://clinicaltrials.gov/study/NCT04471727","created_at":"2021-01-18T21:29:07.037Z","updated_at":"2025-02-25T12:37:38.530Z","phase":"Phase 1/2","brief_title":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","source_id_and_acronym":"NCT04471727 - HPN328-4001","lead_sponsor":"Harpoon Therapeutics, Inc., a subsidiary of Merck \u0026 Co., Inc. (Rahway, New Jersey USA)","biomarkers":" DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)"],"overall_status":"Recruiting","enrollment":" Enrollment 232","initiation":"Initiation: 12/14/2020","start_date":" 12/14/2020","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-20"},{"id":"8e698f4d-2a78-42c5-a620-76e572d7431e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595059","created_at":"2021-01-18T17:40:37.713Z","updated_at":"2024-07-02T16:35:05.958Z","phase":"Phase 1","brief_title":"A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors","source_id_and_acronym":"NCT03595059","lead_sponsor":"AbbVie","biomarkers":" EGFR • HER-2 • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["EGFR • HER-2 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • mirzotamab clezutoclax (ABBV-155)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 07/13/2018","start_date":" 07/13/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-03"},{"id":"b9d29ac1-22f0-48b2-a031-d017175875c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05914116","created_at":"2023-06-22T19:11:45.274Z","updated_at":"2024-07-02T16:35:37.381Z","phase":"Phase 1/2","brief_title":"A Study of DB-1311 in Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT05914116","lead_sponsor":"DualityBio Inc.","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK1 • NTRK3 • NTRK2 • CD276","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12 • NTRK1 mutation • NTRK3 mutation","tags":["EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK1 • NTRK3 • NTRK2 • CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12 • NTRK1 mutation • NTRK3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT324"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 09/05/2023","start_date":" 09/05/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2023-09-12"},{"id":"8bc758ab-0b4b-41e5-93ef-7fefbaef118e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05652855","created_at":"2022-12-15T14:58:22.186Z","updated_at":"2024-07-02T16:35:57.986Z","phase":"Phase 1/2","brief_title":"Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05652855","lead_sponsor":"Minghui Pharmaceutical Pty Ltd","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MHB088C"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/23/2023","start_date":" 01/23/2023","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2023-01-09"}]